ADMA (ADMA Biologics) ROCE %: 41.33% (As of Mar. 2026)

What is ADMA Biologics ROCE %?

ADMA Biologics ADMA -0.54% 64 ROCE % is 41.33% as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ADMA Biologics's annualized ROCE % for the quarter that ended in Mar. 2026 was 41.33%.

ADMA Biologics (NAS:ADMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ADMA Biologics ROCE % Related Terms

ADMA Biologics ROCE % Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics ROCE % Chart

ADMA Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-27.03

-16.80

-1.09

39.20

38.42

ADMA Biologics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															31.84	35.67	39.52	47.41	41.33

64GF Score

ADMA Biologics Inc ADMA

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ADMA Biologics ROCE % Calculation

ADMA Biologics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	189.766	/	( ( (488.678 - 55.542)	+	(624.242 - 69.541) )	/ 2 )
	=	189.766	/	( (433.136	+	554.701)	/ 2 )
	=	189.766	/	493.9185
	=	38.42 %

ADMA Biologics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	236.908	/	( ( (624.242 - 69.541)	+	(665.184 - 73.541) )	/ 2 )
	=	236.908	/	( ( 554.701	+	591.643 )	/ 2 )
	=	236.908	/	573.172
	=	41.33 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 41.33% mean?

ADMA Biologics (ADMA) has a ROCE % of 41.33% as of Mar. 2026.

Is ADMA Biologics' ROCE % too high?

ADMA Biologics' current ROCE % is 41.33%. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does ADMA Biologics' ROCE % compare to ZLAB and HRMY?

ADMA Biologics' ROCE % of 41.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. ADMA Biologics's current ROCE % is 41.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ADMA Biologics stock overvalued right now?

Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current ROCE % is 41.33%. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current ROCE % is 41.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

ROCE %: 41.33%
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Industry Healthcare Biotechnology

Comparable Companies ZLAB HRMY STOK VRDN NUVB KARD PGEN ATAI SLBT GHRS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 465 State Route 17, Ramsey, NJ, USA, 07446

Website https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

64GF Score

Get the complete analysis for ADMA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16

Price

$18.04

GF Value

View ADMA Analysis

See ROCE % data for all stocks →